Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | PLA2G4B | P0C869 | 4/20 | 0.48 |
| ▸ | CETP | P11597 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18800110 | 0.95 | EPHX2 (0.51) | L3MBTL1TDP1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL29242919 | 0.95 | CETP (0.52) | L3MBTL1TDP1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL9540650 | 0.95 | CETP (0.52) | L3MBTL1TDP1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL25269510 | 0.91 | EPHX2 (0.57) | L3MBTL1TDP1EPHX2TSHR | |
| SCHEMBL19032713 | 0.91 | EPHX2 (0.57) | L3MBTL1TDP1EPHX2TSHR | |
| SCHEMBL10081325 | 0.91 | EPHX2 (0.57) | L3MBTL1TDP1EPHX2TSHR | |
| SCHEMBL25118437 | 0.90 | CETP (0.52) | L3MBTL1TDP1ALDH1A1EPHX2CYP3A4 | |
| Adipic Acid SCHEMBL1409802 | 0.87 | ALDH1A1 (0.51) | L3MBTL1TDP1ALDH1A1EPHX2CYP3A4 | |
| SCHEMBL25212789 | 0.86 | MAPT (0.54) | L3MBTL1TDP1EPHX2MAPK1PLA2G4B | |
| SCHEMBL25210921 | 0.86 | MAPT (0.54) | L3MBTL1TDP1EPHX2MAPK1PLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | ASTRAZENECA AB (SE) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181482-A1 | LIPIDS FOR DELIVERY OF NUCLEIC ACID SEGMENTS | SNRPA, F12, ABCB4 | L3MBTL1 480/4885TDP1 1615/4885ALDH1A1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.